Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

ACTRNACTRN12621000881831 : A Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Surgical<br/>TrialTypeSurgical
Trial

OnePhase One

18+Age Over 18

Pancreas<br/>CancersCancer LocationPancreas
Cancers

Surgical,Systemic therapy | Stomach and upper gastrointestinal tractPancreas

Trial Overview Read MoreRead more

This Phase I trial is evaluating the effectiveness of a new cancer treatment (PTM-101) in people with boderline resectable or locally advanced pancreatic cancer.
 

This trial is treating patients with pancreatic ductal adenocarcinoma.

This is a surgical and systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I Study of PTM-101 as Neoadjuvant Therapy for Borderline Resectable or Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Commercial Sponsor

PanTher Therapeutics and Avania Clinical

Summary

PTM-101 is a biodegradable device containing 100mg of paclitaxel. PTM-101 will be placed onto the pancreatic surface overlying the tumour via a laparoscopy. PTM-101 will degrade over approximately 10 weeks.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Medical Oncology
Prahran
Ms Janet Andrew
J.Andrew@alfred.org.au
03 9076 0994

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next